why is tirzepatide compounded with niacinamide Patients GLOWING on Tirzepatide / Niacinamide - JUVVA

The mechanism of GLP-1 agonists is far more direct and potent than berberine's approach

However: Longer-term safety data (5+ years) is still being collected Individual risk factors vary significantly Regular medical monitoring essential for ongoing safety assessment Some individuals develop side effects requiring discontinuation Long-term cardiovascular benefits observed in some trials (SELECT trial with semaglutide) Healthcare providers should regularly reassess whether continued treatment remains appropriate for individual circumstances based on ongoing benefits, risks, and patient preferences

No kitchen-sink blend

The most common reasons for stopping GLP1RAs and tirzepatide are gastrointestinal intolerance and high costs